Translating in vivo metabolomic analysis of succinate dehydrogenase deficient tumours into clinical utility

Ruth T Casey, Mary A McLean, Basetti Madhu, Benjamin G Challis, Rogier Ten Hoopen, Thomas Roberts, Graeme R Clark, Deborah Pittfield, Helen L Simpson, Venkata R Bulusu, Kieran Allinson, Lisa Happerfield, Soo-Mi Park, Alison Marker, Olivier Giger, Eamonn R Maher, Ferdia A Gallagher

Research output: Contribution to journalArticlepeer-review


PURPOSE: Mutations in the mitochondrial enzyme succinate dehydrogenase (SDH) subunit genes are associated with a wide spectrum of tumours including phaeochromocytoma and paraganglioma (PPGL) 1, 2, gastrointestinal stromal tumours (GIST) 3, renal cell carcinoma (RCC) 4 and pituitary adenomas5. SDH-related tumorigenesis is believed to be secondary to accumulation of the oncometabolite succinate. Our aim was to investigate the potential clinical applications of MRI spectroscopy (1H-MRS) in a range of suspected SDH-related tumours.

PATIENTS AND METHODS: Fifteen patients were recruited to this study. Respiratory-gated single-voxel 1H-MRS was performed at 3T to quantify the content of succinate at 2.4 ppm and choline at 3.22 ppm.

RESULTS: A succinate peak was seen in six patients, all of whom had a germline SDHx mutation or loss of SDHB by immunohistochemistry. A succinate peak was also detected in two patients with a metastatic wild-type GIST (wtGIST) and no detectable germline SDHx mutation but a somatic epimutation in SDHC. Three patients without a tumour succinate peak retained SDHB expression, consistent with SDH functionality. In six cases with a borderline or absent peak, technical difficulties such as motion artefact rendered 1H-MRS difficult to interpret. Sequential imaging in a patient with a metastatic abdominal paraganglioma demonstrated loss of the succinate peak after four cycles of [177Lu]-DOTATATE, with a corresponding biochemical response in normetanephrine.

CONCLUSIONS: This study has demonstrated the translation into clinical practice of in vivo metabolomic analysis using 1H-MRS in patients with SDH-deficient tumours. Potential applications include non-invasive diagnosis and disease stratification, as well as monitoring of tumour response to targeted treatments.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalJCO precision oncology
Publication statusPublished - 29 Mar 2018


Dive into the research topics of 'Translating in vivo metabolomic analysis of succinate dehydrogenase deficient tumours into clinical utility'. Together they form a unique fingerprint.

Cite this